FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987200935> ?p ?o ?g. }

• W2987200935 endingPage "5356" @default.
• W2987200935 startingPage "5356" @default.
• W2987200935 abstract "Introdution Optimal treatment of young patients with high-risk diffuse large B-cell lymphoma (DLBCL) remains a matter of debate. With the addition of rituximab, response rates (RR) and overall survival (OS) have improved significantly, but the best treatment option for this subset of patients with high risk DLBCL is not consensual. Historically, these patients are treated with conventional immunochemotherapy protocols (RCHOP - Rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by autologous stem cell transplantation (ASCT) as a consolidation treatment. Several studies tried to clear the exact role of ASCT, and others were design to answer about addition of other drugs to RCHOP, without conclusive results. Recently, our department review the protocol according to the state of the art, and an intensification of treatment was made for high risk DLBCL in young patients (<65 years), without comorbidities. Since then, this group of patients is treated with the RCHOEP protocol (Rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone in addition to etoposide), omitting ASCT. Aim Comparison of conventional immunochemotherapy followed by ASCT with high dose immunochemotherapy in young, high risk patients with DLBCL. Analyze the impact of ASCT in the outcomes. Methods We evaluated 478 patients with confirmed diagnosis of DLBCL at our institution, between January 2012 and December 2017. 10 patients with CNS involvement and 108 patients with primary extranodal disease at diagnosis were excluded. A retrospective analysis was performed in the group of young, high risk patients with DLBCL. For study purpose 2 subgroups were defined: RCHOP plus ASCT (n=17) and RCHOEP (n=32) treated patients. Analysis of survival and statistical comparison between these two subgroups was made using the SPSS computing platform. Results In this study, 360 patients were analyzed. The median follow-up of the cohort was 46 months [4-86 months]. In the subgroup of RCHOP plus ASCT (n=17) the median age at diagnosis was 57 years [22-65]. LDH distribution showed a maximum of 3989 U/L and a minimum of 158 U/L, with a median value of 449 U/L. IPI median value was 3. 5 patients had involvement of extranodal areas and all presented at diagnosis with stage 3 (n=4) or 4 (n=13). Analysis of histological subtype (classified by Hans algorithm) , revealed 9 patients with germinal center DLBCL (GC DLBCL) and 8 patients with activated B Cell DLBCL (ABC DLBCL). Complete response (CR) was obtained in 15 patients and 3 patients relapsed. In the subgroup of RCHOEP (n=32) the median age at diagnosis was 51 years (31-63). LDH range between 150 and 2695 U/L, with a median value of 399 U/L. IPI median value was 3 with a minimum value of 2. 11 patients had involvement of extranodal areas and only 1 patient doesn´t presented with advanced disease at diagnosis. In concern to histological subtype, 18 patients had GC DLBCL and 14 patients had ABC DLBCL. CR was achieved in 28 patients and 4 patients relapse during follow up. Prior to analysis of survival a statistical comparison between the 2 subgroups was performed and did not identify any significant difference between the main demographic and analytical clinical variables (age at diagnosis, sex, ECOG, presence of B symptoms, LDH, hemoglobin concentration, clinical status, medullary involvement, presence of bulky mass, IPI score and histological subtype). As regards the analysis of survival in both subgroups, the median OS was not attained. The 2-year OS was 87,5% in the group of patients treated with RCHOEP and 82% in the subgroup of patients submitted to RCHOP plus ASCT, not presenting this difference statistical value. Conclusion No randomized trials have been conducted comparing R-CHOP and R-CHOEP and there is only one retrospective study population based cohort from the Danish Lyfo Registry comparing young high risk DLBCL treated with R-CHOP or R-CHOEP. This study aims to explore the RCHOEP potential comparing to RCHOP plus ASCT in this peculiar group of patients, as an alternative regimen. Despite the retrospective character of this study, our results demonstrates the non-inferiority of RCHOEP relatively to RCHOP plus ASCT. RCHOEP is an effective treatment for young patients with high risk DLBCL, an excellent alternative, with high efficacy and a tolerable toxicity. This result should be validated in a prospective randomized study. Disclosures No relevant conflicts of interest to declare." @default.
• W2987200935 created "2019-11-22" @default.
• W2987200935 creator A5001898686 @default.
• W2987200935 creator A5009458732 @default.
• W2987200935 creator A5012491849 @default.
• W2987200935 creator A5012718986 @default.
• W2987200935 creator A5019232642 @default.
• W2987200935 creator A5027874480 @default.
• W2987200935 creator A5034189673 @default.
• W2987200935 creator A5048853947 @default.
• W2987200935 creator A5054897950 @default.
• W2987200935 creator A5056762017 @default.
• W2987200935 creator A5065051221 @default.
• W2987200935 creator A5086247792 @default.
• W2987200935 date "2019-11-13" @default.
• W2987200935 modified "2023-10-03" @default.
• W2987200935 title "High Risk DLBCL in Younger Patients: Should ASCT be Declined in the Era Pos-Rituximab?" @default.
• W2987200935 doi "https://doi.org/10.1182/blood-2019-131254" @default.
• W2987200935 hasPublicationYear "2019" @default.
• W2987200935 type Work @default.
• W2987200935 sameAs 2987200935 @default.
• W2987200935 citedByCount "0" @default.
• W2987200935 crossrefType "journal-article" @default.
• W2987200935 hasAuthorship W2987200935A5001898686 @default.
• W2987200935 hasAuthorship W2987200935A5009458732 @default.
• W2987200935 hasAuthorship W2987200935A5012491849 @default.
• W2987200935 hasAuthorship W2987200935A5012718986 @default.
• W2987200935 hasAuthorship W2987200935A5019232642 @default.
• W2987200935 hasAuthorship W2987200935A5027874480 @default.
• W2987200935 hasAuthorship W2987200935A5034189673 @default.
• W2987200935 hasAuthorship W2987200935A5048853947 @default.
• W2987200935 hasAuthorship W2987200935A5054897950 @default.
• W2987200935 hasAuthorship W2987200935A5056762017 @default.
• W2987200935 hasAuthorship W2987200935A5065051221 @default.
• W2987200935 hasAuthorship W2987200935A5086247792 @default.
• W2987200935 hasConcept C126322002 @default.
• W2987200935 hasConcept C141071460 @default.
• W2987200935 hasConcept C143998085 @default.
• W2987200935 hasConcept C2776694085 @default.
• W2987200935 hasConcept C2776755627 @default.
• W2987200935 hasConcept C2778119113 @default.
• W2987200935 hasConcept C2778559949 @default.
• W2987200935 hasConcept C2778720950 @default.
• W2987200935 hasConcept C2779050716 @default.
• W2987200935 hasConcept C2779338263 @default.
• W2987200935 hasConcept C2779429289 @default.
• W2987200935 hasConcept C2780653079 @default.
• W2987200935 hasConcept C2911091166 @default.
• W2987200935 hasConcept C71924100 @default.
• W2987200935 hasConceptScore W2987200935C126322002 @default.
• W2987200935 hasConceptScore W2987200935C141071460 @default.
• W2987200935 hasConceptScore W2987200935C143998085 @default.
• W2987200935 hasConceptScore W2987200935C2776694085 @default.
• W2987200935 hasConceptScore W2987200935C2776755627 @default.
• W2987200935 hasConceptScore W2987200935C2778119113 @default.
• W2987200935 hasConceptScore W2987200935C2778559949 @default.
• W2987200935 hasConceptScore W2987200935C2778720950 @default.
• W2987200935 hasConceptScore W2987200935C2779050716 @default.
• W2987200935 hasConceptScore W2987200935C2779338263 @default.
• W2987200935 hasConceptScore W2987200935C2779429289 @default.
• W2987200935 hasConceptScore W2987200935C2780653079 @default.
• W2987200935 hasConceptScore W2987200935C2911091166 @default.
• W2987200935 hasConceptScore W2987200935C71924100 @default.
• W2987200935 hasIssue "Supplement_1" @default.
• W2987200935 hasLocation W29872009351 @default.
• W2987200935 hasOpenAccess W2987200935 @default.
• W2987200935 hasPrimaryLocation W29872009351 @default.
• W2987200935 hasRelatedWork W2034585655 @default.
• W2987200935 hasRelatedWork W2158890225 @default.
• W2987200935 hasRelatedWork W2888800187 @default.
• W2987200935 hasRelatedWork W2895858698 @default.
• W2987200935 hasRelatedWork W2907658963 @default.
• W2987200935 hasRelatedWork W2987200935 @default.
• W2987200935 hasRelatedWork W3169495907 @default.
• W2987200935 hasRelatedWork W3212185513 @default.
• W2987200935 hasRelatedWork W4250500771 @default.
• W2987200935 hasRelatedWork W4284698212 @default.
• W2987200935 hasVolume "134" @default.
• W2987200935 isParatext "false" @default.
• W2987200935 isRetracted "false" @default.
• W2987200935 magId "2987200935" @default.
• W2987200935 workType "article" @default.